News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Reata Pharmaceuticals, Inc. Contracts ApoCell, Inc. to Detect Innovative Biomarkers in a Phase II Clinical Study of RTA 402 for Diabetic Renal Disease


6/10/2008 8:40:14 AM

HOUSTON--(BUSINESS WIRE)--ApoCell, Houston, Texas, and Reata Pharmaceuticals, Irving, Texas, announce the start of a laboratory study conducted as part of a phase II clinical trial of Reata RTA 402 for the treatment of diabetic renal disease. RTA 402 has also shown promising activity in a recent cancer phase I study of patients with advanced solid tumors.

Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES